Dickran G. Kazandjian, MD

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.